SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination

Cell Reports, Journal Year: 2021, Volume and Issue: 36(3), P. 109415 - 109415

Published: June 29, 2021

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants threatens efforts to contain the disease 2019 (COVID-19) pandemic. number COVID-19 cases and deaths in India has risen steeply, a SARS-CoV-2 variant, B.1.617, is believed be responsible for many these cases. spike protein B.1.617 harbors two mutations receptor binding domain, which interacts with angiotensin converting enzyme (ACE2) constitutes main target neutralizing antibodies. Therefore, we analyze whether more adept entering cells and/or evades antibody responses. enters eight cell lines tested roughly 50% increased efficiency equally inhibited by entry inhibitors. In contrast, resistant against bamlanivimab, an used treatment. antibodies induced infection or vaccination, although less so than B.1.351 variant. Collectively, our study reveals that evasion may contribute rapid spread this

Language: Английский

---

A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics

Current Medical Science, Journal Year: 2021, Volume and Issue: 41(6), P. 1037 - 1051

Published: July 9, 2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of disease 2019 (COVID-19), has caused more than 179 million infections and 3.8 deaths worldwide. Throughout past year, multiple vaccines have already been developed used, while some others are in process being developed. However, emergence new mutant strains SARS-CoV-2 that demonstrated immune-evading characteristics an increase infective capabilities leads to potential ineffectiveness against these variants. The purpose this review article is highlight current understanding immunological mechanisms virus vaccines, as well investigate key variants mutations driving pandemic their impacts on management guidelines. We also discussed technologies for prevention, treatment, detection SARS-CoV-2. In paper, we thoroughly reviewed provided crucial information virology, drugs used its prevention important variant strains. Our paper will be beneficial health care professionals researchers so they can a better basic sciences, clinical treatment COVID-19 during pandemic. This consists most updated available June 21, 2021.

Language: Английский

---

SARS-COV-2 Variants: Differences and Potential of Immune Evasion

Frontiers in Cellular and Infection Microbiology, Journal Year: 2022, Volume and Issue: 11

Published: Jan. 18, 2022

The structural spike (S) glycoprotein of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) plays an essential role in infection and is important target for neutralizing antibody recognition. Mutations the S gene can generate variants concern (VOCs), which improve "viral fitness" through selective or survival advantages, such as increased ACE-2 receptor affinity, infectivity, viral replication, higher transmissibility, resistance to antibodies immune escape, increasing disease severity reinfection risk. Five VOCs have been recognized include B.1.1.7 (U.K.), B.1.351 (South Africa), P.1 (Brazil), B.1.617.2 (India), B.1.1.529 (multiple countries). In this review, we addressed following critical points concerning VOCs: a) characteristics SARS-CoV-2 with mutations gene; b) possible evasion from generated vaccination, previous infection, therapies; c) potential risk new pandemic waves induced by worldwide; d) perspectives further studies actions aimed at preventing reducing impact during current COVID-19 pandemic.

Language: Английский

---

SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape

Cell Host & Microbe, Journal Year: 2022, Volume and Issue: 30(2), P. 154 - 162.e5

Published: Jan. 13, 2022

Characterizing SARS-CoV-2 evolution in specific geographies may help predict properties of the variants that come from these regions. We mapped neutralization a strain evolved over 6 months ancestral virus person with advanced HIV disease South Africa; this was infected prior to emergence Beta and Delta variants. longitudinally tracked tested it against self-plasma convalescent plasma ancestral, Beta, infections. Early similar but multitude mutations found Omicron other It showed substantial incomplete Pfizer BNT162b2 escape, weak by self-plasma, despite pre-dating Delta, also extensive escape infection-elicited neutralization. This example is consistent notion evolving individual immune-compromised hosts, including those disease, gain immune vaccines enhanced immunity, has implications for vaccine breakthrough reinfections.

Language: Английский

---

Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2

Cell Host & Microbe, Journal Year: 2021, Volume and Issue: 29(12), P. 1788 - 1801.e6

Published: Nov. 13, 2021

Previous work found that the co-occurring mutations R203K/G204R on SARS-CoV-2 nucleocapsid (N) protein are increasing in frequency among emerging variants of concern or interest. Through a combination silico analyses, this study demonstrates adaptive, while large-scale phylogenetic analyses indicate associate with emergence high-transmissibility lineage B.1.1.7. Competition experiments suggest 203K/204R possess replication advantage over preceding R203/G204 variants, possibly related to ribonucleocapsid (RNP) assembly. Moreover, virus shows increased infectivity human lung cells and hamsters. Accordingly, we observe positive association between COVID-19 severity sample 203K/204R. Our suggests contribute transmission virulence select variants. In addition spike protein, important for viral spreading during pandemic.

Language: Английский

---